Novo Nordisk | NVO - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
ANI Pharmaceuticals USD 597.21M 34.91M 2026-06
Aurora Cannabis CAD 48.04M 81.94M 2026-03
Bausch Health Companies USD 2.08B 41M 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Canopy Growth CAD 98.72M 11.51M 2026-03
Corcept Therapeutics USD 214.85M 343K 2026-06
Drreddys Laboratories INR 74.33B 1.4B 2026-03
Eli Lilly USD 10.52B 496M 2026-06
GlaxoSmithKline GBP 5.8B 468M 2026-06
Merck USD 15.77B 2.4B 2026-06
Nektar Therapeutics USD 49.12M 8.22M 2026-03
Novartis USD 10.2B 912M 2026-06
Novo Nordisk DKK 44.73B 7.52B 2026-06
Novo Nordisk DKK 6.96B 30.25B 2026-06
Pacira USD 180.54M 7.79M 2026-06
Perrigo USD 290.5M 645.1M 2026-06
Phibro Animal Health USD 361.83M 29.47M 2026-03
Prestige Brands USD 213.19M 7.06M 2026-06
Sanofi EUR 9.92B 607M 2026-06
Supernus Pharmaceuticals USD 1.03B 45.58M 2026-06
Zoetis USD 3.15B 85M 2026-06